NEW YORK, May 5 (GenomeWeb News) - Ann Hagan has been named associate director for extramural activities at the US National Institute of General Medical Sciences, of the National Institutes of Health. Hagan will supervise the Institute's research and research training grant program in the basic biomedical sciences, and will advise the NIGMS director on Institute grant activities.
Hagan has been at NIGMS since 2000, as associate director for extramural activities, and has served as acting associate director since November 2003. Between 1989 and 2000, she was at the National Institute of Diabetes and Digestive and Kidney Diseases, and served as chief of the review branch. Between 1987 and 1989, she was a health scientist administrator in the grants review branch of the National Cancer Institute. Before joining NIH in this administrative capacity, she was an assistant professor of biology at American University. She also held a staff fellowship in 1979 a staff fellow at the National Institute of Mental Health, and served as an assistant professor of biology at George Williams College in Downers Grove, IL. Hagan received BS and MS degrees in biology education and a PhD in physiology, all from the University of Illinois at Urbana-Champaign.
Stephen Kingsmore has been named president of the National Center for Genome Resources and Susan Baxter has been appointed Chief Operating Officer, the Santa Fe, NM firm said Tuesday.
Kingsmore was previously chief operating officer of Molecular Staging and vice president of research of CuraGen. He also has been an assistant professor at the University of Florida in Gainesville. Kingsmore graduated in medicine from the Queen's University of Belfast, Northern Ireland, and completed internship and residency in internal medicine, and a fellowship in rheumatology, at Duke University Medical Center.
Baxter comes to NCGR from Cengent Therapeutics (formerly GeneFormatics), where she was vice president of research and genome analysis. She was previously a tenured researcher at the New York State Department of Health's Wadsworth Center. Baxter received her MS and PhD degrees in chemistry from Northwestern University, Baxter was an NIH postdoctoral fellow at the Institute of Molecular Biology at the University of Oregon.
Sigma-Aldrich has elected eight new directors to its board, the company said Tuesday.
These include Nina Fedoroff, David Harvey, W. Lee McCollum, William O'Neil, Jr., J. Pedro Reinhard, Jerome Sandweiss, D. Dean Spatz, and Barrett Toan.
Axel Ullrich director of the department of molecular biology at the Max Planck Institute of Biochemistry in Martinsried, Germany has been named to lead the Singapore Onco Genome Laboratory beginning in June 2004, the institute said today.
He will be joined by four postdoctoral researchers from Max Plank, including Sylvia Streit, Jens Ruhe, Stefan Hart, and Katja Specht, as well as researchers form the Genome Institute of Singapore and Singapore's Institute of Molecular and Cell Biology.
The Onco Genome Laboratory is a joint research program between the Max Planck Society and the Agency for Science, Technology and Research, or A*STAR and is located in Singapore's Biopolis.
Ullrich is an expert in the field of signal transduction and the development of gene technology-based therapies. He co-founded Sugen, a company that develops small molecule drugs to target signal transduction pathways, in 1991. Sugen was acquired by Pharmacia Upjohn in 1999. He subsequently founded Axxima Pharmaceuticals in 1998, and U3 Pharma in 2002.
Georges Haas has joined the supervisory board of Ingenium, the Munich drug discovery company said today.
Haas retired in 1997 as worldwide head of pharmaceutical research and preclinical development at Ciba-Geigy where he worked in pharmaceutical development for 27 years. Haas received his doctorate in chemistry from the Federal Institute of Technology in Zurich, and completed postdoctoral training at Cornell University, as well as management training at Harvard Business School.
Haas replaces Kate Bingham, general partner of Schroder Ventures Life Sciences, who joined Ingenium's Supervisory Board in 2000 and left at the end of 2003.
Doyle Hill has been appointed vice president and chief technology officer of Integrated NanoTechnologies, a Rochester, NY, developer of nanoscale bioelectronic DNA identification platforms.
Prior to this appointment, Hill was group vice president, research and development worldwide, Ortho-Clinical Diagnostics and vice president, immunodiagnostics business at Johnson & Johnson. He also served for 22 years in management positions in the clinical products and clinical diagnostic divisions of Eastman Kodak. Hill holds a PhD from Oklahoma State University.
Wolfgang Fries has been appointed vice president global human resources at Qiagen, the company said Monday. Fries will work from Qiagen's European headquarters in Hilden, the Netherlands, and will be a member of the company's executive committee.
Before joining Qiagen April 1, Fries served as vice president human resources at GDX Automotive, a subsidiary of GenCorp in Farmington Hills, Michigan. He also has held human resources positions at Faurecia- SAI Automotive Audi.
Don Van Dyke has been appointed vice president of business development at Incogen, the company said Monday. Van Dyke most recently served as a consultant to Incogen, and prior to that, was VP of sales and marketing at Molecular Mining from 2000 to 2003. Prior to this, he was president and CEO of Bio Image, which produced the first physical map of the human genome and performed proteomics analysis. Van Dyke began his career in sales positions at American Scientific Products and Dade Diagnostics.
Cepheid of Sunnyvale, Calif., has appointed David Persing and Mitchell Mroz to its board of directors, the company said May 3.
Persing is vice president of discovery research at Corixa and medical director of the Infectious Disease Research Institute in Seattle. In 1992, Persing established and directed the molecular microbiology laboratory at Mayo Clinic Rochester. Persing obtained his MD and PhD from University of California, San Francisco in 1988. He completed a residency in laboratory medicine at Yale School of Medicine.
Mroz is chairman of the board of Northrop Grumman's Federal Credit Union and retired vice president and general manager of Northrop Grumman's automation & information systems division. Mroz joined Northrop Grumman in 1978. He received a BS in industrial management from Purdue University in 1975 and served in the US Marine Corps Air Wing from 1962 to 1970.
Persing and Mroz join existing board members Cristina Kepner, Thomas Gutshall, John Bishop, Robert Easton, Dean Morton, Kurt Petersen, and Hollings Renton.
Stan Yakatan has been appointed to the board of directors of Phenomenome Discoveries of Saskatoon, Saskatchewan. He has founded or co-founded over 15 companies, and served as an executive at New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific, and Biosearch.
Phenomenome Discoveries uses its metabolite analysis and bioinformatics platform to do non-targeted metabolomic investigation of complex biological samples.
Larry Gold has been appointed to the scientific advisory board of Archemix, the Cambridge, Mass., company said April 28.
Gold has developed high affinity aptamers, single-stranded nucleic acids that bind target molecules in a similar way to that of antibodies, as a researcher at the University of Colorado. He is the founder, chairman, and chief scientific officer at SomaLogic, which develops aptamers for proteomics and diagnostics. He previously founded Nexagen to develop aptamers for therapeutic and diagnostic purposes. Nexagen merged with Gilead Sciences in 1999.
Archemix is developing aptamers for ophthalmic applications.